Introduction
============

From Electronic Health Records to mHealth Applications
------------------------------------------------------

Over the last decade, management of patients in hospitalization units has been supported by the emergence of electronic health records (EHRs) \[[@ref1]\]. This software facilitates portability and processing of pertinent health and pharmacological treatment information \[[@ref2]\]. These systems can support prescription practice and help practitioners determine maximally therapeutic pharmacological treatments while avoiding pitfalls such as off-label use, polypharmacy, and overly high dosages. Moreover, the emergence of electronic prescribing or e-prescribing devices with clinical decision support systems (CDSSs) has significantly reduced diagnosis and prescription error rates \[[@ref3]\]. However, it remains difficult to extract clinically relevant information from current CDSS tools, as these data are often not tailored to the exact needs of the patient and clinician \[[@ref4]\]. The availability of mobile phones and other handheld computers provides the opportunity to improve prescription practices in institutions where e-prescribing systems are not yet available. For example, Web-based and mobile phone--based programs permit the gathering of naturalistic data that can be processed immediately and provide instantaneous decision-making assistance to clinicians \[[@ref5],[@ref6]\]. Overall, the appearance of these devices in medical practice has heralded the mobile health (mHealth) era, which in turn falls under the umbrella of electronic health (eHealth), where mobile devices are used to advance public health \[[@ref7]\]. The combination of high levels of mental illness and high levels of mobile phone usage worldwide highlights the potential for mH^2^ interventions (ie, mHealth mental health interventions) \[[@ref8]\].

Wirelessly connected technologies have also increased communication and data transfer between clinicians and their patients, which further helps achieve these mHealth goals \[[@ref9]\]. The processing of naturalistic data is especially critical given the enormous complexity of individual conditions \[[@ref10]\]. Data mining techniques can also allow for automatic extraction of meaningful data from large clinical databases, which can help answer important treatment and outcome questions and refine best practices. Moreover, this data mining can help develop algorithms and guidelines to help care providers who require assistance \[[@ref11]\]. These algorithms may be of particular interest to prescribers and can be used to improve the incorporation of prescription guidelines into clinical practice \[[@ref12]\].

Challenges in Managing Psychopharmacological Treatments
-------------------------------------------------------

However, despite these technological advances, the management of psychopharmacological treatment still grapples with many challenges. Antipsychotics are widely prescribed in psychiatric inpatient units and, as a result, off-label use is common. Although they are mostly prescribed in schizophrenia spectrum and related disorders, antipsychotics are also used off-label in a range of chronic diseases and they have been utilized as augmentation for depressive disorder \[[@ref13]\], autism spectrum disorders \[[@ref14]\], or off-label use, which is controversial but not uncommon \[[@ref15]\]. For example, one study conducted across 7 provinces within Spain showed that antipsychotics were not only used in schizophrenia (22.8%) but also in other psychiatric disorders such as bipolar disorder (14.4%), depressive disorders (12.5%), personality disorders (9%), substance use disorders (1.3%), and dementia (4.5%), with 32.8% considered off-label uses \[[@ref16]\]. Antipsychotic polypharmacy (APP) is also controversial yet quite common. APP is the use of 2 or more antipsychotics concurrently by a single patient. APP is commonly used against general clinical guideline recommendations \[[@ref17]\]. A recent systematic review of APP prevalence between 1970 and 2009 found in a sample of 1,418,163 patients with mental disorder (82.9% with a diagnosis of schizophrenia) a median APP prevalence of 19.6% across different geographical regions, ranging from 6% to 90%, with higher median prevalence in Asia (32%) and Europe (23%) compared with North America (16%) and Oceania (16.4%) \[[@ref18]\]. APP differs according to treatment setting, requiring more extended use in greater illness severity, such as that in inpatient settings \[[@ref19],[@ref20]\]. In Spanish inpatient settings, APP is common with 47.1% of patients in a psychiatric hospital \[[@ref21]\] and figures between 40% and 50% in psychiatric brief hospitalization units \[[@ref22]\]. These studies highlight the discrepancy between guidelines and the real-world treatment. We can observe a paradigm shift in APP from discouraging all uses of polypharmacy to determining patient profiles that could benefit from polypharmacy \[[@ref23]\]. In a naturalistic observational study, Gaviria et al \[[@ref24]\] analyzed existing EHRs to collect data on prescription habits in a sample of 1765 patients with schizophrenia. Out of the sample of 1765 patients, 505 (28.6%) were receiving treatment with antipsychotic monotherapy, whereas 1229 (69.6%) were receiving 2 or more antipsychotics. Another concern regarding antipsychotic prescription is the use of antipsychotics above their recommended doses. Overly high dosage can increase risk for adverse reactions and increases treatment cost without clear evidence of added therapeutic benefit \[[@ref24]\]. This practice, although prevalent in clinical settings, is discouraged in clinical guidelines \[[@ref25]\]. These challenges highlight the importance of exploring innovative prescription monitoring methods for the field of mental health.

Toward a Mobile Clinical Decision Support System
------------------------------------------------

Given the many proven benefits of EHRs for clinical practice, EHRs may also provide a possible solution to the issues that exist with antipsychotic prescription habits. Specifically, EHRs are a major source of structured data that can provide useful and ecologically valid insights into how antipsychotics are prescribed. These EHR systems, however, presented many limitations that are related to the methodology of such studies. First, conducting clinical research using data produced by EHRs can be challenging, as the timing, quality, and comprehensiveness of the clinical data often do not meet the rigorous standards of clinical research. Furthermore, owing to the architecture of traditional EHRs, data cannot be processed instantaneously to deliver a CDSS. Before delivering a CDSS, data must be deidentified as well as statistically analyzed, which has not yet been automated by software into an instantaneous process. Notably, most studies that use EHRs to describe antipsychotic habits implement retrospective methods \[[@ref26]\]. As a result, researchers and clinicians miss the opportunity to process gathered data in the moment and use these data for clinical decision making. Finally, EHRs are usually only accessible as expensive commercial software packages, which precludes assessment of inpatients treated by institutions outside of large, mainstream health care institutions.

Web-based and mobile phone--based prescription management tools exhibit numerous advantages over these expensive, mainstream EHR software packages. Specifically, the low development cost and increasing popularity of mHealth apps (ie, health-related software applications) have made them particularly accessible across both large and small psychiatric care settings. In addition, mHealth apps often feature simple interfaces, can be used wirelessly from any location with a cell signal, and provide adequate computing power to provide CDSS capability. For the most part, these mHealth apps in mental health have been directly marketed to either consumers or small clinical practice settings. A review of mobile phone apps for schizophrenia found only 5 studies of mobile phone apps for patients with schizophrenia. All examined feasibility, and one assessed the preliminary efficacy \[[@ref27]\]. For example, Nicholas et al \[[@ref7]\] showed that the contents of currently available apps for bipolar disorder are not in line with practice guidelines or established self-management principles.

Taking into consideration the strengths and pitfalls of each of these strategies, our aim was to develop a Web application that could monitor prescription habits in psychiatric inpatient units. This study presents the preliminary step in the development of a CDSS. Our hypothesis was that a Web application developed for this study may be able to describe clinicians' prescriptions in a sample of inpatients. The objective of this study was to describe via the MEmind Web application the prescription habits of antipsychotics in a naturalistic inpatient setting focusing on off-label uses and APP.

The ultimate goal of this MEmind prototype is to allow physicians to provide more effective care while better adhering to clinical guidelines.

Methods
=======

Study Design
------------

This pilot study was a 5-month, multicenter, nonrandomized, and observational feasibility study. Participants were adults admitted in 2 brief psychiatric inpatient units (Fundación Jiménez Díaz Moncloa Hospital and Pontones Hospital, Madrid, Spain).

Setting
-------

The 2 brief psychiatric inpatient units are part of the Department of Psychiatry of the Fundación Jiménez Díaz Hospital, which belongs to the National Health Services and provides medical coverage financed by taxes to a catchment area of \~800,000 people. A total of 4 psychiatrists are in charge of the 20 beds in each of these units. Roughly 14 nurses cover 3 work shifts in both units. Patients admitted were treated as usual. The psychiatrist in charge of the patient proposed participation in the study after verification of the inclusion criteria.

Inclusion and Exclusion Criteria
--------------------------------

Inclusion criteria were either males or females, aged 18 years or older, who were admitted to a psychiatric inpatient unit, and who gave written informed consent. Participants were excluded from the study if they were younger than 18 years, incarcerated, under guardianship, were enrolled in other trials, or were in emergency situations where their state of health did not allow for obtaining written informed consent.

Study Procedure
---------------

During their hospitalization in the psychiatric unit (PU), all patients were assessed with the MEmind Web application after giving written informed consent. The MEmind application was developed for the study by an industrial partner and is available online for download via a secure link provided to the participant via email. The application was designed to gather observational data and to perform ecological momentary assessment (EMA). It has 2 distinct views: the clinician view and the patient view. The "clinician" view is designed to be used by doctors and nurses during their clinical rounds and during their medical or nursing visits (see [Figure 1](#figure1){ref-type="fig"}, which displays the MEmind Web application). MEmind was also designed to capture all the data typically gathered during a standard medical evaluation, including sociodemographic, diagnostic, and pharmacological treatment information. MEmind's design is based on commonly stored information in mental health management. To this end, the care providers can customize the software to add a number of large relevant scales to suit their individual needs (eg, the specific needs of research vs clinical settings). At the time of discharge, we collected patients' sex, age, diagnosis, and treatment types during their stay in the psychiatric unit. As the study was performed in Spanish mental health centers, the Spanish version of the tutorials for mental health professionals was used. In addition to the clinician view, the MEmind program features a patient view that allows patients to track their symptoms using EMA techniques. This feature was not assessed in our study. Medication compliance was not assessed in this study. For the purposes of this study, we monitored patients' diagnoses and clinicians' prescriptions. The only users who accessed the app were the clinicians who recorded their prescriptions directly into MEmind's clinician interface. Clinicians could access the Web application either from a computer or their personal mobile phone.

Clinical diagnoses and treatment prescription were conducted during hospital admission as part to routine psychiatric evaluations that incorporated data from medical records, other research assessments, and clinical interviews. All diagnoses recorded into the MEmind app were coded according to the *International Classification of Diseases, Tenth Revision*, for mental disorders alongside the data from these aforementioned psychiatric evaluations.

![View of the MEmind Web application.](jmir_v19i1e25_fig1){#figure1}

Outcome Measures
----------------

Antipsychotic medication treatments were recorded into the MEmind app and then classified according to the Anatomical Therapeutic Chemical (ATC) classification system and the defined daily dose (DDD). For each patient, the treatment management function of the Web application calculated the average of daily dose prescribed for antipsychotics (N05A ATC code), prescribed daily dose (PDD), PDD 95% CI, and the mean PDD to DDD ratio. Although ATC classification includes lithium and antipsychotics under the N05A code, we chose to include only antipsychotics for the purposes of this study. To compare dosages of various antipsychotics, we used a fixed unit of measurement calculated by dividing the PDD by the DDD. A PDD/DDD ratio greater than 1.5 was defined as excessive dosing \[[@ref28]\]. All analyses were conducted using SPSS version 22.0 (IBM Corporation).

Ethical Considerations
----------------------

The research was in compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) and the standards established by the institutional review board and granting agency. All the participants provided written informed consent after the complete description of the study. Previously, the research protocol was approved by the Ethics Committee of Fundación Jiménez Díaz, Madrid.

Results
=======

Sample Characteristics
----------------------

A total of 359 patients received brief psychiatric care in the 2 psychiatric inpatient units from June 2014 to October 2014. Among them, 353 patients were evaluated with the MEmind application. Of the 6 patients who did not participate in the study, 1 patient refused to participate and 5 patients did not receive the proposal to participate. The distribution of the main psychiatric disorders according to age and sex is presented in [Table 1](#table1){ref-type="table"}.

Out of our total sample, 243 patients had 1 psychiatric diagnosis, with schizophrenia spectrum and related disorders being the most frequent diagnoses. Other diagnoses were comorbid diagnoses and were considered secondary to their psychotic disorder diagnoses. Antipsychotics, alone or in combination with other psychotropic drugs, were used in 217 of the 353 patients (61.5%). Of the 217 patients, 137 (63.2%) were administered pharmacological monotherapy and 80 (36.8%) were administered polytherapy (for details, see [Table 2](#table2){ref-type="table"}).

###### 

Age and sex distribution of psychiatric disorders.

  --------------------------------------------------------------------------------------------------------------------------------
  Psychiatric disorder                Patients with diagnosis, n (%)   Age, %   Sex, %                                      
  ----------------------------------- -------------------------------- -------- -------- ------ ------ ------ ------ ------ ------
  Substance use disorders             79 (22.4)                        19.3     47.4     33.3   0      .02    51.8   48.2   .41

  Schizophrenia and other psychoses   134 (38)                         28.4     37.9     24.2   9.5    .83    42.5   57.5   .79

  Mood disorders                      100 (28.3)                       25.7     23.0     35.1   16.2   .009   54.0   46.0   .238

  Personality disorders               70 (19.8)                        35.4     47.9     16.3   0      .007   52.9   47.1   .505

  Total (N=353)                       \                                27.3     35.5     27.3   9.8    \      48.7   51.3   \
  --------------------------------------------------------------------------------------------------------------------------------

^a^The *P* value was calculated using the chi-square test.

###### 

Antipsychotic medication use according to diagnosis.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diagnosis                                                     Patients with diagnosis, n (%)       Antipsychotic use   Antipsychotic monotherapy   Antipsychotic polytherapy   
  ------------------------------------------------------------- ------------------------------------ ------------------- --------------------------- --------------------------- ---
  **One diagnosis (n=243)**                                                                                                                                                      

  \                                                             Substance use disorders              16 (4.5)            8                           6                           2

  Schizophrenia and other psychosis                             101 (28.6)                           101                 62                          39                          

  Mood disorders                                                69 (19.5)                            51                  33                          18                          

  Anxiety-related disorders                                     24 (6.8)                             5                   4                           1                           

  Personality disorders                                         21 (5.9)                             12                  10                          2                           

  Rest of the diagnoses                                         12 (3.4)                             0                   0                           0                           

  **Comorbidity (n=110)**                                                                                                                                                        

  \                                                             Organic disorders + mood disorders   5 (1.4)             2                           1                           1

  Substance use disorders + schizophrenia and other psychosis   10 (2.8)                             9                   4                           5                           

  Substance use disorders + mood disorders                      6 (1.7)                              6                   4                           2                           

  Substance use disorders + personality disorders               7 (2.0)                              9                   4                           5                           

  Schizophrenia and other psychosis + personality disorders     7 (2.0)                              6                   3                           3                           

  Mood disorders + personality disorders                        6 (1.70)                             4                   2                           2                           

  Anxiety-related disorders + personality disorders             9 (2.5)                              4                   4                           0                           

  Other combinations                                            60 (17)                              0                   0                           0                           

  Total                                                         353                                  217                 137                         80                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Antipsychotic Medication Use Pattern
------------------------------------

The frequencies of prescription according to diagnoses, as a unique or comorbid condition, were as follows: Of the 353 patients, 118 (33.4%, 118/353) patients had a diagnosis of schizophrenia and other psychosis (F20-F29), 86 (24.3%, 86/353) had a diagnosis of mood disorders (F30-F39), 50 (14.1%, 50/353) had a diagnosis of personality disorders (F60-F69), and 33 (9.3%, 33/353) had a diagnosis of anxiety-related disorders (F40-F49; see [Table 2](#table2){ref-type="table"}).

Antipsychotics were prescribed to 217 patients corresponding to a total of 365 antipsychotics prescriptions. In 62 (29.2%) patients, antipsychotics were the only psychotropic drug prescribed; in 40 (18.9%) patients 1 antipsychotic was prescribed and in 22 (10.4%) patients 2 antipsychotics were prescribed. For the remaining 155 patients, antipsychotics were used in combination with other psychotropic drugs. Thus, only 18.9% of our sample were patients in a pure monotherapy antipsychotic regimen. [Table 3](#table3){ref-type="table"} presents the different antipsychotics prescribed, ATC/DDD classification, and doses used in our clinical practice. The antipsychotics used in excessive doses were amisulpride, olanzapine, risperidone, and paliperidone (both their oral and long-acting injectable forms). On the other hand, levomepromazine was used in the lowest dose followed by clotiapine and quetiapine.

The antipsychotics used more frequently in APP were clozapine (81.8%), clotiapine (81.8%), and amisulpride (70.6%) through oral administration and fluphenazine (100%), zuclopenthixol acufase (100%), and zuclopenthixol depot (83.3%) through long-acting injectable forms (for details, see [Multimedia Appendices 1](#app1){ref-type="supplementary-material"} and [2](#app2){ref-type="supplementary-material"}).

###### 

Anatomical Therapeutic Chemical classification with defined daily dose, prescribed daily dose values, and prescribed daily dose to defined daily dose ratio of antipsychotics prescribed.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  No. of prescriptions\   Drug                          ATC^a^ code   DDD^b^ (mg)   Median PDD^c^ (mg)   Mean PDD (mg)   PDD (mg) 95% CI   Mean PDD/DDD^d^
  (N=365)                                                                                                                                  
  ----------------------- ----------------------------- ------------- ------------- -------------------- --------------- ----------------- -----------------
  17                      Amisulpride^e^                N05AL05       400           800                  811.76          652.4-971.1       2.03

  37                      Aripiprazole^e^               N05AX12       15            15                   20.54           16.7-24.4         1.37

  25                      Asenapine^e^                  N05AH05       20            10                   14.4            11.3-17.5         0.72

  11                      Clotiapine^e^                 N05AH06       80            40                   35.45           24.4-46.5         0.44

  11                      Clozapine^e^                  N05AH02       300           350                  345.45          284.2-406.7       1.15

  3                       Fluphenazine^f^               N05AB02       1             0.89                 1.19            0.61-1.78         1.19

  7                       Haloperidol^f^                N05AD01       8             5                    7.63            2.4-12.9          0.95

  3                       Levomepromazine^f^            N05AA01       300           50                   58.33           42.0-74.7         0.19

  36                      Olanzapine^e^                 N05AH03       10            10                   15.76           12.5-19.1         1.58

  22                      Paliperidone^f^               N05AX13       6             10.5                 11.59           9.5-13.7          1.93

  63                      Long-acting paliperidone^f^   N05AX13       2.5           3.57                 4.79            4.34-5.24         1.92

  38                      Quetiapine^f^                 N05AH04       400           150                  228.29          153.5-303.1       0.57

  66                      Risperidone^f^                N05AX08       5             6                    7.61            6.5-8.7           1.52

  1                       Long-acting risperidone^e^    N05AX08       2.7           7.14                 7.14            7.14-7.14         2.64

  10                      Tiapride^e,f^                 N05AL03       400           300                  290             244.3-335.7       0.73

  1                       Ziprasidone^f^                N05AE04       80            120                  120             120.0-120.0       1.50

  2                       Zuclopenthixol acufase^f^     N05AF05       30            25                   25              25-25             0.83

  12                      Zuclopenthixol depot^f^       N05AF05       15            9.5                  10.3            8.8-11.9          0.69
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ATC: Anatomical Therapeutic Chemical.

^b^DDD: defined daily dose.

^c^PDD: prescribed daily dose.

^d^Mean PDD to DDD ratio.

^e^Oral administration.

^f^Injectable administration.

Discussion
==========

Principal Findings
------------------

This study described a reproducible method for performing naturalistic prospective prescription analysis via a Web- and mobile phone--based application prototype, MEmind. This observational study was the first step in the development of a CDSS that may help care providers better monitor their prescriptions and make decisions regarding pharmacological treatment. In this study, we were able to identify polypharmacy, overly high dosage, and off-label use in a psychiatric inpatient setting. We found that APP was used in 35.8% of the patients in our 2 brief psychiatric inpatient units, with clozapine as the oral drug most used in APP and fluphenazine as the long-acting injection drug most used in APP. Antipsychotics were used mostly in schizophrenia spectrum and related psychotic disorders, but they were also prescribed in other nonpsychotic diagnoses. Risperidone and paliperidone, in both their oral and long-acting presentation, were the most prescribed antipsychotics. With respect to dosing, with the exception of only one prescription of long-acting risperidone, amisulpride was the antipsychotic prescribed at highest doses, whereas levomepromazine was the antipsychotic prescribed at lowest doses.

In our sample, the oral antipsychotics most used in APP regimen were clozapine, clotiapine, and amisulpride. One likely explanation for these findings regarding clotiapine in APP is that clotiapine is not principally used for its antipsychotic properties but rather for its hypnotic properties; this interpretation is supported by clotiapine's PDD/DDD ratio of 0.44. Clozapine was used in APP in 81.8% of cases. Out of 11 patients who were administered clozapine, 9 patients received pharmacological polytherapy and only 2 patients received monotherapy with a PDD/DDD ratio of 1.15. Amisulpride was used in APP in 70.6% (12/17) of cases. Our use of these antipsychotics is consistent with their pervasive clinical use in our country \[[@ref21]\] and worldwide \[[@ref29]\].

Clinical guidelines recommend the use of clozapine in APP only for ultraresistant patients with schizophrenia \[[@ref22]\]. This will reduce clozapine dose, minimize adverse effects and allow for the use of amisulpride APP to be the rule rather than the exception \[[@ref29]\]. Moreover, a very common antipsychotic combination is the clozapine augmentation with amisulpride in patients with ultraresistant schizophrenia.

Long-acting antipsychotics were rarely used with first-generation antipsychotics but were used most frequently in APP. Second-generation antipsychotics, however, were used in pharmacological monotherapy and polytherapy in the same proportion. In our sample, long-acting paliperidone has replaced long-acting risperidone (used in only 1 patient) and is used in APP in almost 50% of cases. The use of paliperidone in this inpatient setting probably represents a fluctuation period during the hospitalization.

When observing the range of doses used in our sample, we noticed that the drugs used in higher doses were amisulpride (PDD/DDD = 2.03) as well as paliperidone in its long-acting presentation (PDD/DDD = 1.92) and oral presentation (PDD/DDD = 1.93). Both of these drugs are antipsychotics with a high affinity for dopamine D~2~ receptor blockade. As a D~2~ receptor binding of 70% is necessary for therapeutic benefits \[[@ref30]\], high doses of these antipsychotics are commonly used to better reach this level of binding. Given that many patients arrive at inpatient settings with severe psychopathology, clinicians may attempt to use pharmacotherapies at higher dosages to stabilize patients in shorter amounts of time. On the other hand, levomepromazine, clotiapine, and quetiapine were the antipsychotics used at the lowest doses. Specifically, their PDD/DDD ratios were less than 0.5, which likely reflects levomepromazine and clotiapine being prescribed for nonpsychotic symptoms (such as insomnia or anxiety) and low doses of quetiapine being prescribed for bipolar depression \[[@ref30]\].

Limitations
-----------

To improve acceptance among care providers, diagnoses were provided by psychiatrists rather than being obtained as the result of a structured clinical interview, such as the Structured Clinical Interview for DSM-5 (SCID-5). As shown in other studies, the implementation of EHRs or CDSSs may increase clinician workload \[[@ref26]\]. In order to ease the burden and improve acceptance of the study procedure among clinicians, we did not include in the baseline assessment a structured interview of participants. This "as usual" approach of conducting is also consistent with the noninterventional setting of our study. However, to further assess the effect of implementation of the CDSS on patients' clinical outcomes, a standard assessment will be performed in a forthcoming study.

In this study, we did not report the effect of MEmind on prescription habits. Changes in prescription behaviors have been reported by other studies describing the implementation of an e-prescribing tool \[[@ref31]\]. It could have been of interest to report the effect of having instantaneous feedback from MEmind concerning off-label use. This, however, would have required a distinct methodology relying on a randomized controlled trial and a larger sample, which does not fit with a feasibility study.

Perspectives
------------

This Web- and mobile phone--based application allows data gathering by both care providers and patients. The second phase of the project would be to combine clinical assessment with pharmacological insight. It may be especially relevant for patient monitoring after discharge, given that mHealth EMA is a promising method for reporting the clinical effects of pharmacological management. It will provide momentary assessment of the effects of a drug, including subjective perception of patients' quality of life and health outcomes \[[@ref7]\]. We will also be able to assess these features in the near future. These systems are able to explain how clinical practice is sometimes ahead of available evidence and may help develop better practices and security. At this point, we were able to provide information about drug management under real conditions and highlight points of conflict between ideal and real practice using the Web application. Our project may support the integration of mHealth techniques in prescription management systems and the development of future CDSSs.
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